Redx Pharma signs MSA with OracleBio Ltd to deliver translational biomarker services for pre-clinical R&D programs

Redx Pharma signs MSA with OracleBio Ltd to deliver translational biomarker services for pre-clinical R&D programs -

2011/11/15- After an initial successful collaboration, Liverpool-based drug discovery company, Redx Pharma have recently signed a master services agreement (MSA) with the Glasgow-based, translational biomarker services company, OracleBio Limited. The agreement will allow Redx Pharma to utilise OracleBio's translational biomarker expertise to aid development and add commercial value to its pipeline of over 250 potential new drug candidates.

Dr. Neil Murray, CEO of Redx Pharma commented, "OracleBio provided exactly the right combination of disease area knowledge, practical biomarker services, data interpretation and quality that we look for in a CRO. We believe that their biomarker knowledge and practical capabilities will certainly help us to de-risk our drug discovery efforts and increase our chances of successfully reaching the market".

Director of OracleBio Dr. Lorcan Sherry commented that "The early implementation of translational biomarkers is the key to success with any drug discovery program, providing early go/no-go decisions and reduced attrition. As with most other drug discovery companies, Redx Pharma clearly see the benefit of early inclusion of translational biomarkers in their programs and we are delighted that they have chosen OracleBio as a partner to work on their extensive list of potential new drug candidates".

Fellow Director Dr. John Waller continued "Further to the implementation of sound translational biomarker strategies within their R&D programs, addressing biomarkers in their products' data packages will enhance the likelihood of a successful licensing deal with large Pharma".

OracleBio offers both practical and consultancy biomarker services to Pharma, biotech and other companies within the life sciences sector. Its core services include Digital Image Analysis of histological tissue sections for biomarker and morphological profiling using Definiens state of the art Tissue StudioTM software. OracleBio also has extensive experience of biomarker study management performed through a combination of their internal capabilities and via partnerships with other trusted expert service providers.